

Edgar Filing: FRESENIUS MEDICAL CARE CORP - Form 6-K

FRESENIUS MEDICAL CARE CORP

Form 6-K

January 14, 2005

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

For the month of January 2005

FRESENIUS MEDICAL CARE CORPORATION

(Translation of registrant's name into English)

Else-Kroner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b):82

On December 1, 2004, National Medical Care, Inc., a subsidiary of
Fresenius Medical Care AG (the "Company"), entered into an amended and restated
agreement with Amgen USA, Inc. for the supply of EPOGEN(R) (Epoetin alfa) and
Aranesp(R) (darbepoetin alfa). The amended and restated agreement supersedes and
replaces the supply agreement dated effective January 1, 2004 which was filed
with the Securities and Exchange Commission as Exhibit 4.19 to the Company's
Form 20-F for the year ended December 31, 2003.

The amended and restated supply agreement reduces the term of the
previous agreement by one month and modifies certain rebate programs.

Edgar Filing: FRESENIUS MEDICAL CARE CORP - Form 6-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: January 14, 2005

FRESENIUS MEDICAL CARE
AKTIENGESELLSCHAFT

By: /s/ BEN LIPPS

Name: Ben Lipps
Title: Chief Executive Officer and
Chairman of the Management Board

By: /s/ LAWRENCE ROSEN

Name: Lawrence Rosen
Title: Chief Financial Officer